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Protein C inhibitor (PCI), a plasma serine protease
inhibitor, inhibits several proteases including the anti-
coagulant enzyme, activated protein C (APC), and the
coagulation enzymes, thrombin and factor Xa. Previous
studies have shown that thrombin and APC are inhib-
ited at similar rates by PCI and that heparin accelerates
PCI inhibition of both enzymes more than 20-fold. We
now demonstrate that the thrombin-binding proteogly-
can, rabbit thrombomodulin, accelerates inhibition of
thrombin by PCI '140-fold (k2 5 2.4 3 10
6 in the pres-
ence of TM compared to 1.7 3 104 M21 s21 in the absence
of TM). Most of this effect is mediated by protein-protein
interactions since the active fragment of TM composed
of epidermal growth factor-like domains 4–6 (TM 4–6)
accelerates inhibition by PCI '59-fold (k2 5 1.0 3 10
6 M21
s21). The mechanism by which TM alters reactivity with
PCI appears to reside in part in an alteration of the S2
specificity pocket. Replacing Phe353 with Pro at the P2
position in the reactive loop of PCI yields a mutant that
inhibits thrombin better in the absence of TM (k2 5 6.3 3
105 M21 s21), but TM 4–6 enhances inhibition by this
mutant '9-fold (k2 5 5.8 3 10
6 M21 s21) indicating that
TM alleviates the inhibitory effect of the less favored
Phe residue. These results indicate that PCI is a potent
inhibitor of the protein C anticoagulant pathway at
the levels of both zymogen activation and enzyme
inhibition.
Protein C inhibitor is a heparin-binding plasma serine pro-
tease inhibitor (serpin)1 (1–4). In vivo and in plasma, a signif-
icant percentage of activated protein C (APC) is inhibited by
PCI with various studies reporting 10–50% of the APC in
complex with PCI (5–9). The other major inhibitor of APC is
a1-antitrypsin. Heparin accelerates inhibition of APC by PCI,
but not by a1-antitrypsin.
Originally identified as an inhibitor of activated protein C, it
is now apparent that this inhibitor has a broad specificity,
inhibiting several of the blood coagulation enzymes including
thrombin and factor Xa. In fact, PCI inhibits thrombin better
than APC both in the presence and absence of heparin (4, 10).
This paradoxical effect of inhibition of both coagulation and
anticoagulation proteins raises questions about the physiolog-
ical role of PCI.
Thrombin serves a dual role in coagulation. It clots fibrino-
gen, activates platelets, and feeds back to promote coagulation
by activating cofactors (11). Alternatively, thrombin can bind to
thrombomodulin (TM), and this complex accelerates protein C
activation giving rise to the anticoagulant serine protease, APC
(12). APC then prevents further thrombin formation by inacti-
vating factors Va and VIIIa, two cofactors required for throm-
bin generation (12, 13). In vivo, thrombin inhibition is usually
believed to be due primarily to antithrombin, another heparin-
binding serpin. This inhibition can be catalyzed by vascular
proteoglycans or by thrombin binding to TM (14, 15). TM is a
proteoglycan containing a covalently associated chondroitin
sulfate moiety. Only forms of TM that contain the chondroitin
sulfate enhance inhibition of thrombin by antithrombin (16–
18). The chondroitin sulfate moiety is not, however, required
for protein C activation, a process that appears to involve
conformational changes in the extended binding pocket of
thrombin (19, 20). The influence of TM on thrombin inhibition
by PCI has not been examined fully.
In the present study, we demonstrate that TM potently ac-
celerates inhibition of thrombin by PCI, a process that depends
primarily on protein-protein interactions between thrombin
and TM. These studies provide new insights into the possible
physiological functions of PCI.
EXPERIMENTAL PROCEDURES
Proteins and Reagents—Recombinant human thrombin was pre-
pared as described previously (21). The concentration of purified recom-
binant thrombin was determined by active site titration with p-nitro-
phenyl p9-guanidinobenzoate and agreed with the calculated
concentration based on absorbance at 280 nm (21). Recombinant human
PCI and Phe3533 Pro mutant of PCI were expressed and purified from
a baculovirus expression system as described previously (3, 22). The
concentration of recombinant PCI was calculated based on thrombin
active site titration and immunoassay as described (3). Recombinant
human TM 4–6 fragment (23) and rabbit lung TM (24) were isolated by
the cited methods. All proteins were homogeneous by acrylamide gel
electrophoresis in sodium dodecyl sulfate. Polybrene was purchased
from Sigma. Spectrozyme TH was purchased from American Diagnos-
tica, Greenwich, CT, and S2266 was purchased from Kabi Pharmacia/
Chromogenix, Franklin, OH.
Thrombin Inhibition with PCI—The rate of inhibition of human
thrombin was measured under pseudo-first order rate conditions by
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both discontinuous and continuous assay methods. In the discontinuous
assay method, both the inhibition reaction and the determination of
residual thrombin activity were done in 96-well plates at room temper-
ature in 20 mM Tris-HCl (pH 7.5), 0.1 M NaCl (TBS) containing 2 mg/ml
bovine serum albumin, as described (3, 4). Thrombin (0.5 nM) was
incubated with at least a 10-fold excess of PCI (10 nM) at room temper-
ature in the presence and absence of saturating concentrations of TM
(50 nM) or TM 4–6 (100 nM). For assays in the absence of TM, 0.1 mg/ml
Polybrene was also included in the buffer. Polybrene was added to
ensure that trace heparin contamination of PCI would not influence the
inhibition rate. However, the rates of PCI inhibition of thrombin in the
presence or absence of Polybrene were similar indicating that PCI
preparations were essentially free of heparin. After a period of time (30
s to 30 min depending on the reaction rates), Spectrozyme TH (SPTH)
in TBS buffer containing 1 mg/ml Polybrene (to block the chondroitin
sulfate moiety of TM) was added to give a final concentration of 0.2 mM.
Following color development, the absorbance at 405 nm was measured
with a Vmax Kinetic Microplate Reader (Molecular Devices, Menlo Park,
CA). Rate constants were calculated using the equation:
k2 5 ~2ln a!/t @I# (Eq. 1)
where a is residual proteinase activity, t is time, and [I] is the PCI
concentration (3, 4). All experiments were performed in triplicate wells,
and all experiments contained control wells in which the assay buffer
had replaced PCI. In all experiments it was ensured that less than 10%
chromogenic substrate was utilized and all inhibition assays were per-
formed by time course analysis to obtain at least 50% enzyme inhibition
for calculation of inhibition rates.
As mentioned above, the PCI concentration in this discontinuous
assay method was 10 nM. In the presence of TM and higher concentra-
tions of PCI (i.e. 30 nM), the rate of inactivation was fast, and, in 15 s,
more than 90% of thrombin activity was inhibited. To demonstrate the
concentration dependence of PCI inhibition in the presence of TM, the
alternative method of continuous inhibition assay was employed. In
this method, the inhibition reaction was carried out in the presence of
a competing chromogenic substrate as described (20, 25). In this case,
50 ml of 1 nM human thrombin (0.5 nM final) in complex with saturating
concentrations of TM (50 nM final) or TM 4–6 (100 nM final) were added
to wells of a 96-well plate that contained 50 ml of PCI at final concen-
trations ranging from 3.1 to 100 nM and SPTH (0.2 mM final), and the
absorbance at 405 nm was measured at 20-s time intervals immediately
after thrombin addition. S2266 (0.5 mM) with a lower affinity for throm-
bin was employed to monitor thrombin inhibition by PCI in the absence
of TM. The PCI concentration had to be increased to 250 nM to obtain
reasonable rates of inhibition under these conditions. The Km values
that were determined and used in Equation 3 were 5.6 mM for SPTH
with thrombin, 6.0 mM for the rabbit TM-thrombin complex, and 5.8 mM
for the TM 4–6-thrombin complex. The Km of thrombin for S2266 was
236 mM.
The apparent pseudo-first order rate constant of inhibition was es-
timated by fitting the absorbance at 405 nm versus time into the
following equation:
Ab 5 A0/kapp 3 ~1 2 e2kapp3t! 1 Ab0 (Eq. 2)
where t is the time of the inhibition, Ab is the absorbance at 405 nm at
time t, Ab0 is the absorbance at 405 nm at time 0, A0 is the thrombin
activity at time 0, and kapp is the apparent pseudo-first order rate
constant of inhibition. To correct for the presence of chromogenic sub-
strate, the pseudo-first order rate constant of inhibition k9 was given by:
k9 5 kapp 3 ~1 1 @S#/Km! (Eq. 3)
where [S] is the concentration of the chromogenic substrate, SPTH or
S2266, and Km is the Michaelis-Menten constant of thrombin for SPTH
or S2266. Both methods of inhibition rate constant measurements gave
similar results. The ENZFITTER computer program (R. J. Leatherbar-
row, Elsevier, Biosoft) was used for data analysis.
RESULTS
Thrombin inhibition by PCI was examined in the presence
and absence of saturating levels of rabbit TM containing chon-
droitin sulfate and recombinant human TM fragment contain-
ing only the epidermal growth factor-like repeats 4–6 and
lacking the chondroitin sulfate by a discontinuous assay
method as shown in Fig. 1. The rate of inactivation of the bound
thrombin was increased dramatically by both forms of TM. The
acceleration of inhibition by rabbit TM was approximately 2–3
times more effective than TM 4–6 (Fig. 1 and Table I). These
results indicate that, unlike TM-dependent acceleration of the
inhibition of thrombin with antithrombin (16, 18), the TM-de-
pendent acceleration of thrombin inhibition by PCI involves
primarily protein-protein interactions rather than glycosami-
noglycan-protein interactions.
In the presence of TM, the rate of inhibition was too fast to
allow accurate assessment of the PCI concentration depend-
ence of thrombin inhibition. As an alternative, the continuous
assay method in the presence of SPTH as the competing chro-
mogenic substrate was used to demonstrate the rate enhance-
ment by TM and TM 4–6 with various concentrations of PCI.
As shown in Fig. 2, in the presence of TM, inhibition was rapid,
inhibitor concentration-dependent, and complete. Fig. 3 shows
that the k9 values are linear with PCI concentration. Note that
with 100 nM PCI, virtually all thrombin activity was inhibited
within 500 s. Similar results were obtained with TM 4–6 (data
not shown). In contrast, in the absence of TM, the same con-
centration of PCI (100 nM) with SPTH as the competing chro-
mogenic substrate failed to inhibit thrombin effectively (data
not shown). In the absence of TM, S2266 was used as the
competing chromogenic substrate to estimate the rate con-
stants by the continuous assay method (Table I).
To allow comparisons of reaction rates, the k2 values for
thrombin inhibition by PCI in the absence and presence of TM
or TM 4–6 were determined. These values were determined by
both the discontinuous and continuous assay methods from
inhibition progress curves in the presence of competing sub-
strate as described under “Experimental Procedures.” For the
discontinuous assay, 17 independent inhibition reactions were
performed in the presence of rabbit TM and 12 reactions in the
presence of TM 4–6. The k2 values determined by the discon-
tinuous assays are given in the top lines of each section of Table
I, and the values in the presence of competing substrate are
given in the middle line of each section. In most cases, the
values obtained by these two assay methods agreed within a
factor of 2. Therefore, to simplify presentation of the influence
of TM on the inhibition rate, the k2 values were averaged, and
the average value was used to calculate the fold enhancement
by TM. The average value is given in the third line of each
section of Table I.
Comparison of the rate constants in Table I reveals that TM
4–6 accelerates thrombin inhibition by PCI approximately 59-
fold. Rabbit TM containing the chondroitin sulfate is only 2–3
times more effective. Taken together, these results indicate
FIG. 1. Time course of thrombin inhibition by PCI in the ab-
sence or presence of TM and TM 4–6. Thrombin (0.5 nM) was
incubated with PCI (10 nM) in the absence (M) or presence of 50 nM TM
(E) or 100 nM TM 4–6 (l) in TBS buffer containing 2 mg/ml bovine
serum albumin. At indicated time points, chromogenic substrate SPTH
in TBS containing 1 mg/ml Polybrene was added to a final concentration
of 0.2 mM, and, after the color development, the remaining amidolytic
activity of uninhibited thrombin was determined as described under
“Experimental Procedures.” Solid lines were obtained by nonlinear
regression analysis of data obtained from the average of three experi-
ments using a first order rate equation.
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that the protein-protein interactions are the most important
contribution to the acceleration of thrombin inhibition by PCI.
The potential mechanisms by which the protein-protein in-
teractions between TM and thrombin might augment PCI in-
hibition were examined by analyzing thrombin inhibition by a
PCI mutant in the presence and absence of TM 4–6. The
sequence of PCI from the P3 to the P39 residues in the reactive
center is Thr-Phe-Arg-Ser-Ala-Arg. Previous kinetic studies
have illustrated that Phe in the P2 position fits poorly into the
S2 specificity pocket of thrombin (26, 27) in contrast to Pro
which is ideally suited to fit into this pocket (28). Mutation of
Phe353 (the P2 residue) to Pro resulted in a PCI mutant that
inhibited thrombin '37-fold better (k2 5 6.3 3 10
5 M21 s21)
than wild type PCI. TM 4–6 enhanced inhibition by this mu-
tant only 9-fold (k2 5 5.8 3 10
6 M21 s21) versus the 59-fold
enhancement for wild type PCI suggesting that interaction of
TM 4–6 with thrombin allowed thrombin to accommodate the
larger and more hydrophobic Phe residue.
DISCUSSION
The observation that PCI reacts rapidly with thrombin in
complex with TM suggests that physiologically PCI functions
primarily to augment coagulation reactions and does so by
inhibiting both protein C activation and APC itself. The rate of
thrombin-TM complex inhibition by PCI is considerably more
rapid than the rate of inhibition of free thrombin by antithrom-
bin even allowing for the higher concentrations of antithrombin
in the circulation (88 nM versus 2.3 mM). At room temperature,
the calculated time to inhibit 50% of the thrombin bound to TM
with plasma levels of PCI would be 3–4 s and with antithrom-
bin would be 30 s. On thrombin-TM complexes that contain
chondroitin sulfate, antithrombin may contribute more signif-
icantly to inhibition (calculated half-life, based on literature
values, would be 2–6 s) (16, 17). In cell culture and probably in
vivo, the addition of chondroitin sulfate to human thrombo-
modulin appears to be incomplete (29). With chondroitin-free
TM, PCI is likely to be a major inhibitor of the complex. In
addition to cell-associated chondroitin-free forms of TM, solu-
ble TM generated by elastase proteolysis lacks the chondroitin
sulfate, and soluble forms of TM are found at moderately high
levels in patients with vascular diseases or inflammatory con-
ditions (30). PCI may play a major role in inhibiting thrombin
bound to these different forms of TM.
PCI is synthesized in the liver, testis, prostate, and kidney
(31, 32). It is of interest that TM has been observed on several
cell types not in contact with blood (33, 34). Given the tissue
distribution of PCI, it is possible that PCI plays a role in
inhibition of thrombin-TM complexes in the extravascular
space. Examination of alternative sites of synthesis of this
inhibitor may provide additional insights into the physiological
function of the inhibitor.
At a biochemical level, these studies draw clear distinctions
between the requirements for inhibition of thrombin bound to
TM by the two serpins, antithrombin and PCI. With PCI,
occupancy of anion-binding exosite 1 by TM 4–6 is sufficient for
acceleration of inhibition by PCI with the chondroitin contrib-
uting only a 2–3-fold additional acceleration. In contrast, TM
4–6 or full-length TM devoid of the chondroitin sulfate fail to
accelerate thrombin inhibition by antithrombin (16, 18). This
suggests that TM-dependent acceleration of thrombin inhibi-
tion by PCI is largely dependent on conformational changes in
thrombin resulting from the protein-protein interactions be-
tween thrombin and TM.
The mechanisms involved in allowing PCI to react rapidly
with the thrombin-TM complex are likely to be due to the
conformational changes that occur during complex formation in
the extended binding pocket of thrombin. Comparison of TM
4–6 acceleration of thrombin inhibition by the wild type PCI
(Phe at the P2 position) with the mutant PCI with Pro at the P2
position revealed that the TM 4–6 acceleration fell from
'59-fold to'9-fold. We interpret these data to suggest that TM
4–6 allows thrombin to accept bulkier and/or more hydropho-
bic residues at the P2 position. Based on modeling and kinetic
data, Phe would not fit well into the S2 pocket of thrombin in
the absence of TM (26, 27). TM could allow thrombin to interact
with Phe more favorably if, for instance, TM elicited conforma-
tional changes in the large insertion loop (the 60 loop) that
forms the upper portion of the S2 specificity pocket (28). Pre-
TABLE I
The second order association rate constants of PCI and PCI F353P
mutant inhibition of thrombin
PCI PCI F353P
M
21 s21 M21 s21
Thrombin 2.0 6 0.3 3 104a 9.6 6 1.7 3 105
1.4 6 0.1 3 104b 3.0 3 105c
Average 1.7 3 104d 6.3 3 105
Thrombin-TM 2.7 6 0.8 3 106 1.3 6 0.8 3 107
2.0 6 0.8 3 106 6.9 6 1.5 3 106
Average 2.4 3 106 1.0 3 107
Thrombin-TM 4–6 1.2 6 0.3 3 106 7.1 6 2.4 3 106
8.1 6 0.8 3 105 4.5 3 106c
Average 1.0 3 106 5.8 3 106
a The values in the top lines are the average of more than 10 inde-
pendent measurements with 6S.D. determined by the discontinuous
assay method.
b The values in the middle lines are the average of 2–6 independent
measurements with 6 S.D. determined by the continuous assay by
analysis of the progress curves in the presence of competing chromo-
genic substrate as described under “Experimental Procedures.”
c Single measurements.
d The average k2 values from two methods of measurements used in
comparisons are shown in the third line.
FIG. 2. Typical progress curves for inhibition of thrombin by
PCI in the presence of TM. Thrombin (0.5 nM) in complex with TM
(50 nM) was added to reactions containing 0.2 mM SPTH and varying
concentrations of PCI in TBS buffer containing 2 mg/ml bovine serum
albumin. The concentrations of PCI in reactions were: 0 (L), 3.1 nM (),
6.3 nM (M), 12.5 nM (l), 25 nM (), 50 nM (f), and 100 nM (E). The
pseudo-first order association rate constant (k9) for inhibition was de-
termined by fitting the data to Equations 2 and 3 (only every 100-s
values are plotted).
FIG. 3. Linear dependence of k* values versus the concentra-
tion of PCI. The pseudo-first order association rate constants of Fig. 2
are plotted versus the concentration of PCI. The slope of the straight
line represents the second order association rate constant of inhibition.
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vious studies examining inhibition of thrombin by bovine pan-
creatic trypsin inhibitor have suggested that this loop can exist
in multiple conformations (35).
The observation that protein-protein interactions between
thrombin and TM accelerate reaction with PCI represents an-
other example of significant enhancement of thrombin reactiv-
ity with naturally occurring protein substrates and inhibitors.
The other examples are protein C activation and single-chain
urokinase-type plasminogen activator inactivation (36, 37).
The exact mechanism of single-chain urokinase-type plasmin-
ogen activator inactivation has not been studied in depth, but
protein C activation, like the inhibition of thrombin by PCI,
appears to involve a conformational change in the active center
of thrombin that overcomes interactions with residues that do
not interact well within the extended binding pocket of throm-
bin in the absence of TM (38). The data presented here in
combination with previous studies suggest that the S3, S2, and
S39 pockets of thrombin are all altered by interaction with TM.
The observation that reactivity of PCI with thrombin is selec-
tively altered by interaction with TM opens new approaches for
investigating the molecular mechanisms by which TM switches
the specificity of thrombin from a clot-promoting to a clot-
inhibiting enzyme.
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